Comparative evaluation of the new FDA approved THxID™-BRAF test with high resolution melting and sanger sequencing

Since patients diagnosed with BRAF V600E and V600K mutated advanced melanoma show response to treatment with MAP kinase inhibitors, several sensitive methods have been developed to determine the V600 allele status of melanoma patients.